Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1178-1661
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings ; day:11 ; month:3 ; year:2017 ; pages:1-12
The Patient ; (11.3.2017), 1-12
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Tomaszewski, Erin L.
- Beteiligte Personen und Organisationen
-
Moise, Pierre
Krupnick, Robert N.
Downing, Jared
Meyer, Margaret
Naidoo, Shevani
Holmstrom, Stefan
SpringerLink (Online service)
- DOI
-
10.1007/s40271-017-0227-y
- URN
-
urn:nbn:de:1111-201704029832
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tomaszewski, Erin L.
- Moise, Pierre
- Krupnick, Robert N.
- Downing, Jared
- Meyer, Margaret
- Naidoo, Shevani
- Holmstrom, Stefan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Ureter metastatic castration-resistant prostate cancer: a case report
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management